Adam Crystal - 01 Nov 2023 Form 4 Insider Report for Tango Therapeutics, Inc. (TNGX)

Role
President, Research & Development
Signature
/s/ Douglas Barry, attorney-in-fact
Issuer symbol
TNGX
Transactions as of
01 Nov 2023
Net transactions value
-$62,994
Form type
4
Filing time
02 Nov 2023, 16:49:54 UTC
Previous filing
02 Mar 2023
Next filing
05 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TNGX Common Stock Sale $62,994 -7,507 -8.5% $8.39 81,250 01 Nov 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 7,507 shares that were acquired on October 31, 2023 pursuant to the Tango Therapeutics, Inc. 2021 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).

Remarks:

President, Research & Development